(132 days)
No
The device description details a lateral flow immunoassay based on antigen-antibody reactions, which is a purely chemical and physical process. There is no mention of any computational analysis, algorithms, or learning processes that would indicate the use of AI or ML.
No
This device is a diagnostic test for detecting methadone in urine, intended to screen for drug presence, not to provide therapy or treatment.
Yes
The device is intended for the qualitative detection of methadone in human urine and provides a preliminary analytical result, which is then used to determine the need for further confirmatory testing. This function aligns with the definition of a diagnostic device.
No
The device description clearly outlines a physical, lateral flow immunoassay strip that utilizes chemical reactions and a membrane. There is no mention of software as the primary or sole component of the device.
Based on the provided text, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The device is intended for the "qualitative detection of methadone in human urine". This clearly indicates it is used to test a biological sample (urine) in vitro (outside the body) to gain information about a person's health status (presence of methadone).
- Device Description: The description details an "immunoassay" that uses a "membrane strip" and "colloidal gold-antibody complex" to detect the presence of methadone in a sample. This is a typical description of an in vitro diagnostic test.
- Performance Studies: The performance studies involve testing "samples" (urine specimens) and comparing the results to other diagnostic methods like Syva Emit II and GC/MS. This further confirms its use as a diagnostic tool.
- Predicate Device: The predicate device listed, "InstaCheck'-Drug Screen-Methadone Test," is also an in vitro diagnostic device for drug screening.
Therefore, all the evidence points to the 'RapidOne'-Methadone Test being an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
'RapidOne'-Methadone Test is used for the qualitative detection of methadone in human urine. This immunoassay is a simplified qualitative screening method that provides only a preliminary result for use in determining the need for additional or confirmatory testing, i.e., GC/MS.
'RapidOne'-Methadone Test is a one-step, lateral flow immunoassay for the detection of methadone in urine.
'RapidOne'-Methadone Test is intended for the qualitative detection of methadone in human urine at 300 ng/ml.
Product codes
DJR
Device Description
The assay employed in the 'RapidOne'-Methadone' Test is based on the same principle of highly specific reaction between antigens and antibodies.
This assay is a one-step, immunoassay in which a specially labeled drug (drug conjugate) competes with drug that may be present in the sample for the limited number of binding sites on the antibody. The test device consists of a membrane strip onto which a drug conjugate has been immobilized. A colloidal gold-antibody complex is dried at one end of a membrane. In the absence of any drug in the urine sample, the colloidal goldantibody moves with the urine by capillary action to contact the immobilized drug coniugate. An antibody-antigen reaction occurs forming a visible line in the 'test' area. The formation of a visible line in the 'test' area occurs when the test is negative.
When drug is present in the urine sample, the drug or metabolite will compete with the immobilized drug conjugate in the test area for the limited antibody sites on the colloidal gold-antibody complex. If sufficient amount of drug is present, it will fill all of the available binding sites, thus preventing attachment of the labeled antibody to the drug conjugate. An absence of a color band (line) in the 'test' area is indicative of a positive result.
A control band (line), comprised of a different antibody/antigen reaction, is present on the membrane strip. The 'control; line is not influenced by the presence or absence of drug in the urine, and therefore, should be present in all reactions.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
'RapidOne'-Methadone Test is intended for professional use. It is not intended for over the counter sale to nonprofessionals. The assay is easy to perform, but should not be used without proper supervision.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
'RapidOne'-Methadone Test was compared to 'InstaCheck'-Drug Screen-Methadone Test. Ninety (90) samples were selected for evaluation, fifty (50) of which were found to be drug-free and forty (40) tested as positive by Syva Emit II. The forty positive specimens were confirmed as positive and quantified by GC/MS. Both immunaoassays correctly identified all the specimens that contained no drug as negative. GC/MS analyses were performed on samples that were screened as positive. Specimens, ranging in concentration of 146 to 1072 ng/ml were shown to be positive by both immunoassays.
Reproducibility was evaluated using control urines containing methadone concentrations above and below the stated cut-off. Forty (40) replicates were run at each concentration by three different operators.
Key Metrics
'RapidOne'-Methadone Test will detect 300 ng/ml of methadone in urine.
| Concentration (ng/ml) | # | RDS Result |
|---|---|---|
| No drug | 120 | 0 |
| 150 | 120 | 6 |
| 225 | 120 | 106 |
| 375 | 120 | 120 |
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.3620 Methadone test system.
(a)
Identification. A methadone test system is a device intended to measure methadone, an addictive narcotic pain-relieving drug, in serum and urine. Measurements obtained by this device are used in the diagnosis and treatment of methadone use or overdose and to determine compliance with regulations in methadone maintenance treatment.(b)
Classification. Class II (special controls). A methadone test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
NOV 2 0 2001
510(k) Summary
Submitter's Name/Address:
American Bio Medica Corporation 122 Smith Road Kinderhook, NY 12106
Contact Person: Henry Wells VP Product Development Phone: 518 758 8158 Fax: 518-758 8171
Date of Preparation of this Summary:
Device Trade or Proprietary Name:
Device Common/Usual Name or Classification Name:
Henry Wells
VP Product Development
Phone: 518 758 8158
Fax: 518-758 8171
September 21, 2001
'RapidOne'-Methadone Test
Methadone test system
Classification Number/Class
[no classification regulation]/ClassII
This 510(k) Summary is being submitted in accordance with the requirements of 21 CFR 807.92.
The assigned 510(k) number is: K012164
Predicate Device: Forefront Diagnostics, Inc. 'InstaCheck' Drug Screen-Methadone Test. (510(k) No. K992325)
Test Description:
The assay employed in the 'RapidOne'-Methadone' Test is based on the same principle of highly specific reaction between antigens and antibodies.
This assay is a one-step, immunoassay in which a specially labeled drug (drug conjugate) competes with drug that may be present in the sample for the limited number of binding sites on the antibody. The test device consists of a membrane strip onto which a drug conjugate has been immobilized. A colloidal gold-antibody complex is dried at one end of a membrane. In the absence of any drug in the urine sample, the colloidal goldantibody moves with the urine by capillary action to contact the immobilized drug coniugate. An antibody-antigen reaction occurs forming a visible line in the 'test' area. The formation of a visible line in the 'test' area occurs when the test is negative.
1
When drug is present in the urine sample, the drug or metabolite will compete with the immobilized drug conjugate in the test area for the limited antibody sites on the colloidal gold-antibody complex. If sufficient amount of drug is present, it will fill all of the available binding sites, thus preventing attachment of the labeled antibody to the drug conjugate. An absence of a color band (line) in the 'test' area is indicative of a positive result.
A control band (line), comprised of a different antibody/antigen reaction, is present on the membrane strip. The 'control; line is not influenced by the presence or absence of drug in the urine, and therefore, should be present in all reactions.
Intended use:
'RapidOne'-Methadone Test is used for the qualitative detection of methadone in human urine. This immunoassay is a simplified qualitative screening method that provides only a preliminary result for use in determining the need for additional or confirmatory testing, i.e., GC/MS.
Performance Characteristics:
'RapidOne'-Methadone Test will detect 300 ng/ml of methadone in urine.
'RanidOne'-Methadone Test was compared to 'InstaCheck'-Drug Screen-Methadone Test. Ninety (90) samples were selected for evaluation, fifty (50) of which were found to be drug-free and forty (40) tested as positive by Syva Emit II. The forty positive specimens were confirmed as positive and quantified by GC/MS. Both immunaoassays correctly identified all the specimens that contained no drug as negative. GC/MS analyses were performed on samples that were screened as positive. Specimens, ranging in concentration of 146 to 1072 ng/ml were shown to be positive by both immunoassays.
Reproducibility was evaluated using control urines containing methadone concentrations above and below the stated cut-off. Forty (40) replicates were run at each concentration by three different operators.
| Concentration
| (ng/ml) | # | RDS Result | |
|---|---|---|---|
| No drug | 120 | 0 | 120 |
| 150 | 120 | 6 | 114 |
| 225 | 120 | 106 | 14 |
| 375 | 120 | 120 | 0 |
Conclusion:
'RapidOne'-Methadone Test is substantially equivalent to Forefront Diagnostics, Inc. 'InstaCheck'-Methadone Test for the qualitative detection of methadone in human urine.
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular, with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the top half of the circle. Inside the circle is an abstract symbol that resembles a stylized human figure or a bird in flight, composed of three curved lines.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Henry Wells, Ph.D. American Bio Medica Corporation 122 Smith Road Kinderhook, NY 12106
NOV 2 0 2001
K012164 Re:
Trade/Device Name: 'RapidOne' - Methadone Test Regulation Number: 21 CFR 862.3620 Regulation Name: Methadone test system Regulatory Class: Class II Product Code: DJR Dated: September 28, 2001 Received: October 4, 2001
Dear Dr. Wells:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed nothroution. I its results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, (301) 591-1500. Tradition for at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or 1301) 443-6597 or at its internet address "http://www.fda.gov/cdrb/dsmaldsmamain.html".
Sincerely yours,
Steven Gutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
NOV 2 0 2001
510(k) Number (if known):_____________________________________________________________________________________________________________________________________________________
'RapidOne'-Methadone Test Device Name:
Indications For Use:
'RapidOne'-Methadone Test is a one-step, lateral flow immunoassay for the detection of methadone in urine.
'RapidOne'-Methadone Test is intended for the qualitative detection of methadone in human urine at 300 ng/ml.
'RapidOne'-Methadone Test is interided for professional use. It is not intended for over the counter sale to nonprofessionals. The assay is easy to perform, but should not be used without proper supervision. This inonprotessionalis. The assay is casy to portunity out stood that provides only a preliminary result for use in immunitiassay is a smipmod qualitative occernatory testing, i.e., gas-chromatography/mass spectrometry (GC/MS).
'RapidOne'-Methadone Test provides only a preliminary analytical result. A more specific alternate chemical method must be used in order to obtain a more confirmed result. GC/MS is the preferred confirmatory method. Clinical and professional judgment should be applied to any drug of abuse test result, particulary when preliminary results are used.
Lean Loons
(Division Sign-Off)
Cooper
Division of Clinical Laboratory Devices
510(k)-Number/0/2/64
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use √
(Per 21 CFR 801.109)
OR
32
Over-The-Counter Use
(Ontinual Format 1-7-96)